<DOC>
	<DOCNO>NCT01138436</DOCNO>
	<brief_summary>This Phase II , randomize , control , two-center pilot study design ass safety efficacy MEBO treatment 14 subject VLUs . Subjects meet entry criterion randomly assign 1:1 ratio 8 week treatment either MEBO SOC ( 7 subject per treatment arm ) .</brief_summary>
	<brief_title>A Clinical Study Safety Efficacy MEBO Wound Ointment Subjects With Venous Leg Ulcers</brief_title>
	<detailed_description>To assess safety efficacy MEBO treatment 14 subject VLUs . Subjects meet entry criterion randomly assign 1:1 ratio 8 week treatment either MEBO SOC ( 7 subject per treatment arm ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>1 . Male female ≥18 year age . 2 . Able willing provide inform consent . 3 . Able willing comply protocol visit procedure . 4 . A fullthickness VLU open continuously ≥4 week ≤1 year . 1 . Ulcer nonvenous hypertensive pathophysiology . 2 . Known suspected allergy component MEBO . 3 . Malignancy target ulcer limb . 4 . Received another investigational device drug within 30 day enrollment . 5 . Noncompliance screen runin period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Venous Leg Ulcers , VLU</keyword>
</DOC>